Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.
Mina Hassan-ZahraeeZhan YeLi XiElizabeth DushinJulie LeeJacek RomatowskiJaroslaw LeszczyszynSilvio DaneseWilliam J SandbornChristopher BanfieldJeremy D GaleElena PeevaRandy S LongmanCraig L HydeKenneth E HungPublished in: Journal of Crohn's & colitis (2024)
Blood and microbiome biomarkers stratify endoscopic, histological, and tissue molecular responses to ritlecitinib, which may help guide future precision medicine approaches to UC treatment. ClinicalTrials.gov NCT02958865.